Search Results

Containing any of the words

Only of the type

A 20-week Study Comparing Patient-adjusted Versus Physician-adjusted Titration of BIAsp 30 Combined With Metformin in Type 2 Diabetes Patients Uncontrolled on NPH Insulin Drug Clinical Trial

A phase 3, multi-center, open-label, randomized study of oral ABL001 versus bosutinib in patients with Chronic Myelogenous Leukemia in chronic phase (CML-CP), previously treated with 2 or more tyrosine kinase inhibitors Drug Clinical Trial

A phase 3, multi-center, open-label, randomized study of oral ABL001 versus bosutinib in patients with Chronic Myelogenous Leukemia in chronic phase (CML-CP), previously treated with 2 or more tyrosine kinase inhibitors Drug Clinical Trial

EPIK-B4: A Phase II, multicenter, randomized, open-label, active-controlled study to assess the safety and efficacy of dapagliflozin + metformin XR versus metformin XR during treatment with alpelisib (BYL719) in combination with fulvestrant in participants with HR+, HER2-, advanced Breast Cancer with a PIK3CA mutation following progression on/after endocrine-based therapy Drug Clinical Trial

Phase 3, Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of PF-07055480 (Recombinant AAV2/6 Human Factor VIII Gene Therapy) in Adult Male Participants with Moderately Severe to Severe Hemophilia A (FVIII:C≤1%) Drug Clinical Trial

"Study H9X-MC-GBGC is a Phase 3, randomized, double-blind, placebo-controlled trial withan open-label extension that investigates the effect of the addition of dulaglutide (0.75 and1.5 mg/week) or placebo weekly to metformin and/or basal insulin on change from baselinein hemoglobin A1c at 26 weeks in children and adolescents with type 2 diabetes mellitus" Drug Clinical Trial

"Study H9X-MC-GBGC is a Phase 3, randomized, double-blind, placebo-controlled trial with an open-label extension that investigates the effect of the addition of dulaglutide (0.75 and 1.5 mg/week) or placebo weekly to metformin and/or basal insulin on change from baseline in hemoglobin A1c at 26 weeks in children and adolescents with type 2 diabetes mellitus" Drug Clinical Trial

Gulf Accreditation Center Renews Accreditation Certificate in the Inspection of Bottled Water Plants for SFDA News

SFDA Alerts about Inaccurate Recommendations of Accu-Chek® Connect Application for Diabetes Management Warnings

SFDA Alerts about Inaccurate Recommendations of Accu-Chek® Connect Application for Diabetes Management Warnings